UK-CAB 62: HIV generic medication

Friday 21 April 2017

 Programme

09.20-09.40 Arrival, tea and refreshments
09.40-10.00 Welcome and introductions, UK-CAB updates, Company pre-meeting (Garry to lead)
10.00-11.30 Company meeting: MSD
11.30-11.45 BREAK
11.45-12.30 CROI feedback – Simon Collins
12.30-14.00 LUNCH
14.00-15.15 Invited speakers:

  1. Switching to generic ARVs (commissioning) – Janette Harper, NHS England
  2. Switching to generic ARVs (HIV pharmacist) – Nadia Naous, Imperial College NHS Trust
15.30-15.45 BREAK
15.45-16.45 MSD feedback
BHIVA feedback
Community reps feedback
Reflection and feedback of the meeting Member updates
16.45 AOB
17.00 Meeting close

Presentations from this meeting

MSD pre-meeting
MSD – MSD virology pipeline update
MSD – Doravirine Phase 3
MSD – Raltegravir once daily study
MSD – Subgroup analyses of Raltegravir once daily study
CROI 2017 feedback
Generic HIV drugs
Use of generic medication: Commissioning perspective
BHIVA spring conference 2017 feedback

Background reading

Generic drugs – questions and answers
Q & A on generic drugs

Generics – the facts: Andrew Hill
Andrew Hill’s presentation at the BHIVA Spring conference 2017. He discusses the new era of generic HIV drugs that are WHO approved, bioequivalent at low cost. Shouldn’t the NHS consider buying these? (Podcast not yet available)

Living with HIV: Switching to generic HIV meds by Jim Fielder
Article from www.boyz.co.uk on switching from branded HIV drugs to generic drugs by Jim Fielder.

Generic HIV drugs and HIV care in the UK
Article from HIV i-Base guide explaining generic drugs and how HIV generic drugs are used in the NHS.

The cost of HIV treatment
This is a US article with useful facts and information regarding the cost of using generic drugs.

Video:
Andrew Hill – Glasgow 2016, 29min
Keynote presentation:  Treatment for cancer, HIV & viral hepatitis in Europe using low cost generic drugs

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

Edit
Published: April 25, 2017
Last edited: May 25, 2017